Israel - inglês - Ministry of Health

lapidot medical import and marketing ltd - amikacin as sulfate - solution for infusion - amikacin as sulfate 5 mg / 1 ml - amikacin - amikacin b braun is indicated in the short-term treatment of gram-negative organisms, including pseudomonas and some gram-positive organisms.sensitive gram-negative organisms include; pseudomonas aeruginosa, escherichia coli., indole-positive and indole-negative proteus spp., klebsiella, enterobacter and serratia spp., minea-herralae, citrobacter freundii, salmonella, shigella, acinetobacter and providencia spp.the principal gram-positive organism sensitive to amikacin is staphylococcus aureus, including some methicillin-resistant strains. amikacin b braun has some activity against other gram-positive organisms including certain strains of streptococcus pyogenes, enterococci and diplococcus pneumoniae.

Canadá - inglês - Health Canada

searchlight pharma inc - amikacin (amikacin sulfate) - solution - 250mg - amikacin (amikacin sulfate) 250mg - aminoglycosides

Canadá - inglês - Health Canada

vpi pharmaceuticals inc - amikacin (amikacin sulfate) - solution - 500mg - amikacin (amikacin sulfate) 500mg - aminoglycosides

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - amikacin, quantity: 500 mg (equivalent: amikacin sulfate, qty 667.5 mg) - injection, solution - excipient ingredients: sulfuric acid; sodium metabisulfite; sodium citrate dihydrate; water for injections - amikacin ajs injection is indicated in the short-term treatment of serious infections caused by susceptible strains of gram negative bacteria (see microbiology).,staphylococcus aureus, including methicillin resistant strains, is the principal gram positive organism sensitive to amikacin.,the use of amikacin in the treatment of staphylococcal infections should be restricted to second line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of staphylococcus who have failed to respond or are allergic to other available antibiotics.,amikacin ajs injection is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used.,in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug maybe indicated because of the possibility of infections due to gram positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in vitro mixing of the two drugs causes inactivation of amikacin.,clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra-abdominal organs, postoperative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - amikacin, quantity: 500 mg (equivalent: amikacin sulfate, qty 667.5 mg) - injection, solution - excipient ingredients: sulfuric acid; sodium citrate dihydrate; sodium metabisulfite; water for injections - amikacin rmb injection is indicated in the short-term treatment of serious infections caused by susceptible strains of gram negative bacteria (see microbiology).,staphylococcus aureus, including methicillin resistant strains, is the principal gram positive organism sensitive to amikacin.,the use of amikacin in the treatment of staphylococcal infections should be restricted to second line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of staphylococcus who have failed to respond or are allergic to other available antibiotics.,amikacin rmb injection is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used.,in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug maybe indicated because of the possibility of infections due to gram positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in vitro mixing of the two drugs causes inactivation of amikacin.,clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra-abdominal organs, postoperative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

Canadá - inglês - Health Canada

sandoz canada incorporated - amikacin (amikacin sulfate) - liquid - 250mg - amikacin (amikacin sulfate) 250mg - aminoglycosides

Canadá - inglês - Health Canada

marcan pharmaceuticals inc - amikacin (amikacin sulfate) - solution - 500mg - amikacin (amikacin sulfate) 500mg - aminoglycosides

Canadá - inglês - Health Canada

omega laboratories limited - amikacin (amikacin sulfate) - solution - 250mg - amikacin (amikacin sulfate) 250mg - aminoglycosides

Canadá - inglês - Health Canada

hikma canada limited - amikacin (amikacin sulfate) - solution - 250mg - amikacin (amikacin sulfate) 250mg

Canadá - inglês - Health Canada

jamp pharma corporation - amikacin (amikacin sulfate) - solution - 250mg - amikacin (amikacin sulfate) 250mg